Report
Jacob Mekhael

MaaT Pharma MaaT013 EAP data shows continued benefit, phase 3 topline in Jan 2025

MaaT presented updated results from the early access program (EAP) for lead candidate MaaT013 (microbiome therapy, enema formulation) in aGvHD in Europe during the American Society of Hematology (ASH) conference. We continue to be encouraged by the strong responses observed in the subset of 58 patients resembling the population enrolled in the phase 3 (ARES) trial, which in our view provides comfort ahead of the upcoming topline readout in January 2025. We reiterate our € 14 TP and BUY rating.
Underlying
MAAT PHARMA SA

Provider
KBC Securities
KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

 

Analysts
Jacob Mekhael

Other Reports on these Companies
Other Reports from KBC Securities
Guy Sips ... (+7)
  • Guy Sips
  • Jacob Mekhael
  • Lynn Hautekeete
  • Michiel Declercq
  • Sharad Kumar S.P
  • Thomas Couvreur
  • Wim Hoste

ResearchPool Subscriptions

Get the most out of your insights

Get in touch